ID   NOZ
AC   CVCL_3079
SY   NOZAWA; NOZC-1
DR   EFO; EFO_0010973
DR   BioGRID_ORCS_Cell_line; 1160
DR   BioSample; SAMN03472480
DR   cancercelllines; CVCL_3079
DR   Cell_Model_Passport; SIDM01812
DR   Cosmic; 1122352
DR   Cosmic; 2629294
DR   Cosmic; 2674061
DR   DepMap; ACH-001607
DR   JCRB; JCRB1033
DR   JCRB; NIHS0283
DR   Wikidata; Q54930937
RX   CelloPub=CLPUB00469;
RX   DOI=10.1007/BF02348185;
RX   PubMed=2543327;
RX   PubMed=3154020;
RX   PubMed=32293552;
RX   PubMed=32899426;
RX   PubMed=39026794;
CC   Part of: Biliary tract cancer cell line atlas.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: 40-48 hours (CelloPub=CLPUB00469); 30 hours (PubMed=32293552); 48 hours (PubMed=3154020); 30 hours (Note=Lot 09162008) (JCRB=JCRB1033).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (DepMap=ACH-001607).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Unspecified (DepMap=ACH-001607).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; RNAseq.
CC   Misspelling: NO2; Cosmic=2629294.
CC   Discontinued: JCRB; NIHS0283; true.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): DepMap=ACH-001607; JCRB=JCRB1033
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 8,12
ST   D16S539: 9,11
ST   D18S51: 12
ST   D21S11: 30,31
ST   D3S1358: 15,17
ST   D5S818: 11,13
ST   D7S820: 10,11
ST   D8S1179: 9,14
ST   FGA: 17
ST   Penta D: 11,13
ST   Penta E: 12,17
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 19
DI   NCIt; C3844; Gallbladder carcinoma
DI   ORDO; Orphanet_56044; Carcinoma of gallbladder and extrahepatic biliary tract
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   48Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 30
//
RX   CelloPub=CLPUB00469;
RA   Homma S.;
RT   "Studies on the establishment and some biological characteristics of
RT   cultured human liver cancer cell lines. Their growth, functional and
RT   morphological characteristics and temperature sensitivities.";
RL   Jikeikai Med. J. 32:289-315(1985).
//
RX   DOI=10.1007/BF02348185;
RA   Kawada M., Aizaki H., Fukaya K.-i., Niiya M., Matsuura T., Sujino H.,
RA   Hasumura S., Nagamori S., Toda G.;
RT   "Morphological changes in human gall bladder carcinoma cell line-NOZ
RT   due to epirubicin and doxorubicin.";
RL   Med. Electron Microsc. 27:175-177(1994).
//
RX   PubMed=2543327;
RA   Hasumura S., Nagamori S., Fujise K., Homma S., Sujino H., Matsuura T.,
RA   Shimizu K., Niiya M., Kameda H.;
RT   "Combination therapy of hyperthermia and other methods in liver and
RT   bile tract cancers -- evaluation of these methods using cancer cell
RT   lines in vitro.";
RL   Gan To Kagaku Ryoho 16:1905-1912(1989).
//
RX   PubMed=3154020;
RA   Homma S., Hasumura S., Nagamori S., Kameda H.;
RT   "Establishment and characterization of a human gall bladder carcinoma
RT   cell line NOZ.";
RL   Hum. Cell 1:95-97(1988).
//
RX   PubMed=32293552; DOI=10.1186/s40659-020-00282-7; PMCID=PMC7158131;
RA   Garcia P., Bizama C., Rosa L., Espinoza J.A., Weber H.,
RA   Cerda-Infante J., Sanchez M., Montecinos V.P., Lorenzo-Bermejo J.,
RA   Boekstegers F., Davila-Lopez M., Alfaro F., Leiva-Acevedo C.,
RA   Parra Z., Romero D., Kato S., Leal P., Lagos M., Roa J.C.;
RT   "Functional and genomic characterization of three novel cell lines
RT   derived from a metastatic gallbladder cancer tumor.";
RL   Biol. Res. 53:13.1-13.17(2020).
//
RX   PubMed=32899426; DOI=10.3390/cancers12092510; PMCID=PMC7565451;
RA   Scherer D., Davila-Lopez M., Goeppert B., Abrahamsson S.,
RA   Gonzalez Silos R., Nova I., Marcelain K., Roa J.C., Ibberson D.,
RA   Umu S.U., Rounge T.B., Roessler S., Lorenzo-Bermejo J.;
RT   "RNA sequencing of hepatobiliary cancer cell lines: data and
RT   applications to mutational and transcriptomic profiling.";
RL   Cancers (Basel) 12:2510.1-2510.14(2020).
//
RX   PubMed=39026794; DOI=10.1101/2024.07.04.601970; PMCID=PMC11257448;
RA   Vijay V., Karisani N., Shi L., Hung Y.-H., Vu P., Kattel P., Kenney L.,
RA   Merritt J., Adil R., Wu Q.-B., Zhen Y.-L., Morris R., Kreuzer J.,
RA   Kathiresan M., Herrera Lopez X.I., Ellis H., Gritti I.G., Lecorgne L.,
RA   Farag I., Popa A., Shen W., Kato H., Xu Q., Balasooriya E.R., Wu M.-J.,
RA   Chaturantabut S., Kelley R.K., Cleary J.M., Lawrence M.S., Root D.E.,
RA   Benes C.H., Deshpande V., Juric D., Sellers W.R., Ferrone C.R., Haas W.,
RA   Vazquez F., Getz G., Bardeesy N.M.;
RT   "Generation of a biliary tract cancer cell line atlas reveals
RT   molecular subtypes and therapeutic targets.";
RL   bioRxiv 2024:07.04.601970-07.04.601970(2024).
//